JP2011528797A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528797A5
JP2011528797A5 JP2011519175A JP2011519175A JP2011528797A5 JP 2011528797 A5 JP2011528797 A5 JP 2011528797A5 JP 2011519175 A JP2011519175 A JP 2011519175A JP 2011519175 A JP2011519175 A JP 2011519175A JP 2011528797 A5 JP2011528797 A5 JP 2011528797A5
Authority
JP
Japan
Prior art keywords
amount
subject
cardiac troponin
angiogenic therapy
reference amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519175A
Other languages
English (en)
Japanese (ja)
Other versions
JP5606438B2 (ja
JP2011528797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059505 external-priority patent/WO2010010153A1/en
Publication of JP2011528797A publication Critical patent/JP2011528797A/ja
Publication of JP2011528797A5 publication Critical patent/JP2011528797A5/ja
Application granted granted Critical
Publication of JP5606438B2 publication Critical patent/JP5606438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519175A 2008-07-23 2009-07-23 抗血管新生療法を受容可能な被験体の同定 Active JP5606438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161014 2008-07-23
EP08161014.9 2008-07-23
PCT/EP2009/059505 WO2010010153A1 (en) 2008-07-23 2009-07-23 Identification of subjects being susceptible to anti-angiogenesis therapy

Publications (3)

Publication Number Publication Date
JP2011528797A JP2011528797A (ja) 2011-11-24
JP2011528797A5 true JP2011528797A5 (enExample) 2012-01-12
JP5606438B2 JP5606438B2 (ja) 2014-10-15

Family

ID=40162929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519175A Active JP5606438B2 (ja) 2008-07-23 2009-07-23 抗血管新生療法を受容可能な被験体の同定

Country Status (5)

Country Link
US (1) US9983213B2 (enExample)
EP (1) EP2321651B1 (enExample)
JP (1) JP5606438B2 (enExample)
ES (1) ES2644723T3 (enExample)
WO (1) WO2010010153A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
SG195208A1 (en) 2011-06-02 2013-12-30 Almac Diagnostics Ltd Molecular diagnostic test for cancer
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
JP6371294B2 (ja) * 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Dll4アンタゴニストによる処置の方法およびモニタリング
WO2014087156A1 (en) 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
JP2002539161A (ja) * 1999-03-15 2002-11-19 ボストン ライフ サイエンシズ,インコーポレーテッド. トロポニンサブユニット、それらの断片および相同体を含む医薬組成物ならびに血管形成を抑制するためのそれらの使用方法
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001061048A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
DE60233301D1 (de) 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
ES2421556T3 (es) * 2004-06-15 2013-09-03 Hoffmann La Roche Utilización de hormonas cardíacas para diagnosticar el riesgo de sufrir complicaciones cardiovasculares como consecuencia de medicamentos cardiotóxicos
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
EP1986012B1 (en) * 2005-01-24 2012-06-06 F. Hoffmann-La Roche AG The use of Bnp-type peptides for assessing the risk of suffering from heart failure as a consequence of volume overload
US7531172B2 (en) * 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
JP2009536727A (ja) 2006-04-04 2009-10-15 シングレックス,インコーポレイテッド 高感度のマーカー分析および分子検出のための方法および組成物
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
EP1890154B1 (en) 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP2089059A2 (en) 2006-11-10 2009-08-19 Genentech, Inc. Method for treating age-related macular degeneration
JP5306218B2 (ja) * 2006-11-21 2013-10-02 エフ.ホフマン−ラ ロシュ アーゲー トロポニンTおよびNT−proBNPの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法
EP2324358A1 (en) 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Monitoring anti-angiogenesis therapy

Similar Documents

Publication Publication Date Title
JP2011528797A5 (enExample)
WO2016094761A3 (en) Test apparatus and methods for st2 cardiac biomarker
JP2011506917A5 (enExample)
WO2013132347A3 (en) Improved elisa immunoassay for calprotectin
JP2015519564A5 (enExample)
JP2015502547A5 (enExample)
JP2013533977A5 (enExample)
JP2012073260A5 (enExample)
JP2018535404A5 (enExample)
HK1223361A1 (zh) 用於预测肠易激综合征诊断的途径特异性测定
Chowdhury et al. The use of biomarkers in the patient with heart failure
JP2015520378A5 (enExample)
JP2013545988A5 (enExample)
JP2013060443A5 (enExample)
WO2011061944A8 (ja) 蛍光免疫測定方法
WO2013083781A3 (en) Biomarkers and test panels useful in systemic inflammatory conditions
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
WO2013092611A3 (en) Method for the detection of free binding partner of a multispecific binder
MX349661B (es) Metodo para la deteccion de una molecula de union de un enlazador multiespecifico.
JP2014533372A5 (enExample)
BR112012019475A8 (pt) uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
WO2018183966A3 (en) METHODS OF QUANTIFICATION OF INSULIN AND PEPTIDE C
RU2012148711A (ru) Способ и набор для диагностики злокачественной опухоли
JP2013527437A5 (enExample)
WO2012032345A3 (en) Biomarker signatures and uses thereof